Aurinia Pharmaceuticals, Inc. (AUP) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ANI Pharmaceuticals, Inc.

Aurinia Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

Iovance Biotherapeutics, Inc.

Maravai Lifesciences Holdings, Inc.

Twist Bioscience Corp.

Merus NV

Xencor, Inc.

Summit Therapeutics, Inc.

Spyre Therapeutics, Inc.

Vir Biotechnology, Inc.

Why is Aurinia Pharmaceuticals, Inc. ?

With a growth in Operating Profit of 19.6%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 9 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD 167.2 MM
NET PROFIT(HY) Higher at USD 245.15 MM
ROCE(HY) Highest at 64.98%

With ROE of 49.68%, it has a fair valuation with a 3.26 Price to Book Value

Over the past year, while the stock has generated a return of 92.15%, its profits have risen by 920.1% ; the PEG ratio of the company is 0

High Institutional Holdings at 62.26%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating Performance

The stock has generated a return of 92.15% in the last 1 year, much higher than market (S&P 500) returns of 20.34%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Aurinia Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Aurinia Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Aurinia Pharmaceuticals, Inc.

92.15%

4.11

46.18%

S&P 500

20.34%

1.56

13.03%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

41.38%

EBIT Growth (5y)

26.11%

EBIT to Interest (avg)

-74.91

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.85

Sales to Capital Employed (avg)

0.56

Tax Ratio

4.69%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

62.26%

ROCE (avg)

19.90%

ROE (avg)

3.27%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.26

EV to EBIT

13.07

EV to EBITDA

11.19

EV to Capital Employed

7.55

EV to Sales

5.36

PEG Ratio

0.01

Dividend Yield

ROCE (Latest)

57.78%

ROE (Latest)

49.68%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 167.2 MM

NET PROFIT(HY)

Higher at USD 245.15 MM

ROCE(HY)

Highest at 64.98%

NET SALES(Q)

Highest at USD 77.71 MM

INTEREST COVERAGE RATIO(Q)

Highest at 4,596.54

RAW MATERIAL COST(Y)

Fallen by -6.29% (YoY

OPERATING PROFIT(Q)

Highest at USD 46.52 MM

OPERATING PROFIT MARGIN(Q)

Highest at 59.86 %

PRE-TAX PROFIT(Q)

Highest at USD 43.93 MM

-6What is not working for the Company

NET PROFIT(Q)

At USD 34.36 MM has Fallen at -52.41%

DEBT-EQUITY RATIO (HY)

Highest at -54.64 %

Here's what is working for Aurinia Pharmaceuticals, Inc.

Operating Cash Flow

Highest at USD 167.2 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 77.71 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Interest Coverage Ratio

Highest at 4,596.54

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit

Highest at USD 46.52 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at 59.86 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD 43.93 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD 43.93 MM has Grown at 51.72%

over average net sales of the previous four periods of USD 28.95 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Raw Material Cost

Fallen by -6.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Aurinia Pharmaceuticals, Inc.

Net Profit

At USD 34.36 MM has Fallen at -52.41%

over average net sales of the previous four periods of USD 72.2 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -54.64 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio